{"prompt": "['SPONSOR: Mehmet Asim Bilen, MD', 'TITLE: Neoadjuvant Lenvatinib with pembrolizumab in Patients with Locally Advanced', 'Nonmetastatic Clear Cell Renal Cell Carcinoma', 'IND NUMBER: 147484', 'Co-Principal Investigator:', 'Mehmet Asim Bilen, MD', 'Winship Cancer Institute of Emory University', 'Department of Hematology and Medical Oncology', '1365 Clifton Road NE, B4301, Atlanta, GA 30322', 'Phone: 404-778-3693', 'Fax: 404-778-3366', 'Email: mbilen@emory.edu', 'Co-Principal Investigator:', 'Viraj Master, MD, PhD', 'Emory University', 'Department of Urology', '1365 Clifton Rd, Atlanta, GA 30322', 'Phone: 404-778-4898', 'Email: vmaster@emory.edu', 'Co-Investigators:', 'Jacqueline Theresa Brown, MD', 'Winship Cancer Institute of Emory University', 'Department of Hematology and Medical Oncology', '1365 Clifton Road NE, Atlanta, GA 30322', 'Phone: 404-778-1900', 'Email:jacqueline.theresa.brown@emory.edu', 'Omer Kucuk, MD', 'Winship Cancer Institute of Emory University', 'Department of Hematology and Medical Oncology', '1365 Clifton Road NE, Atlanta, GA 30322', 'Phone: 404-778-1900', 'Email: omer.kucuk@emory.edu', 'Bradley C. Carthon, MD, PhD', 'Winship Cancer Institute of Emory University', 'Department of Hematology and Medical Oncology', '1365 Clifton Road NE, Atlanta, GA 30322', 'Phone: 404-778-1900', 'Email: bradley.c.carthon@emory.edu', 'Page 1', 'Version Date: 05/08/2020']['Haydn T. Kissick, PhD', 'Emory University', 'Department of Urology', '1462 Clifton Rd, Room 420', 'Atlanta, Georgia, 30322', 'Phone: 617 259 8364', 'Email: haydn.kissick@emory.edu', 'Statistician:', 'Yuan Liu, PhD, MS', 'Winship Cancer Institute of Emory University', '718 Gatewood Rd NE', 'Atlanta, GA 30322', 'Phone: 404-778-1989', 'Email: yliu31@emory.edu', 'Study Coordinator:', 'TBD', 'Supplied Agent:', 'pembrolizumab (Merck), lenvatinib (Merck)', 'Page 2', 'Version Date: 05/08/2020']['1.0 TRIAL SUMMARY', 'Abbreviated Title', 'Neoadjuvant Lenvatinib Plus Pembrolizumab in Locally Advanced,', 'Non-Metastatic Clear Cell Renal Cell Carcinoma', 'Trial Phase', 'Phase 2', 'Clinical Indication', 'Neoadjuvant therapy', 'Trial Type', 'Single-Arm', 'Type of control', 'N/A', 'Route of administration', 'PO (lenvatinib) and IV (pembrolizumab)', 'Trial Blinding', 'N/A', 'Treatment Groups', 'Single-Arm', 'Number of trial participants', '17', 'Estimated enrollment period', '1 year', 'Estimated duration of trial', '3 years', 'Estimated average length of', '12 weeks', 'treatment per patient', '2.0 TRIAL DESIGN', '2.1 Trial Design', 'Patients with locally advanced, non-metastatic clear cell renal cell carcinoma (T3Nx or TanyN+)', 'will be enrolled to receive neoadjuvant lenvatinib plus pembrolizumab for 4 cycles (12 weeks)', 'before surgical resection.', \"Each subject's course will consist of four periods, all of which are depicted in the Trial Flow\", 'Chart (Section 6.0):', 'A Pre-Treatment Period in which subjects are consented and undergo screening', 'assessments to be qualified for the study.', 'A Treatment Period in which subjects receive study treatment and undergo study', 'assessments. This period will end at the time of completion of lenvatinib plus', 'pembrolizumab, or when the patient withdraws consent or experiences unacceptable', 'toxicity.', 'A Post-Treatment Period in which subjects no longer receive study treatment and', 'undergo kidney surgery. This period also includes intraoperative and post-operative', 'period.', 'A Long-Term Follow-up Period in which subjects will be followed after surgery until the', \"patient's withdrawal of consent or loss to follow up, death, or study termination\", 'Page 3', 'Version Date: 05/08/2020']\n\n###\n\n", "completion": "END"}